Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
Profile

Chris Mason, MD, PhD, FRSB, FRCS, FMedSci

Chris Mason is Founder and CSO at AVROBIO, Inc. a clinical-stage, gene therapy company [NASDAQ AVRO]. He is a clinician-scientist with 30 years of cell and gene therapy experience spanning R&D, clinical medicine, and bioprocessing. He is a Full Professor of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London. In 2019, he was elected as a Fellow of The Academy of Medical Sciences. He is also a Founder and Board Director of OriBiotech Ltd., a company focused on next-generation fully-automated cell therapy bioprocessing, and Board Director of Krystal Biotech, Inc. [NASDAQ KRYS]. Dr. Mason was instrumental in the founding of the Alliance for Regenerative Medicine (ARM), the UK-Israel Science Council, and the London Regenerative Medicine Network. He is on the SAB of several companies and the UK Cell & Gene Therapy Catapult, and the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM). Dr. Mason is Senior Editor of the journals Cell and Gene Therapy Insights and Regenerative Medicine.



Return to SAB Page
REQUEST QUOTE